![Joshua Cohen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Actieve functies van Joshua Cohen
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Haystack Oncology, Inc.
![]() Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Part of Quest Diagnostics, Inc., Haystack Oncology, Inc. is a biopharmaceutical company based in Baltimore, MD. The Haystack MRD test is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in various locations. The company developed Haystack MRD™, a next-generation tumor-informed approach for the measurement of minimal residual disease. Haystack Oncology works with biopharmaceutical companies to advance important therapeutics to markets, from early phase clinical development to companion diagnostics. The test accelerates clinical development with better MRD testing unmatched sensitivity and specificity for confident MRD detection. The company leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development. The company was founded in 2021 by Kenneth W. Kinzler, Nickolas Papadopoulos, Joshua Cohen, Bert Vogelstein, and the CEO is Dan Edelstein. Haystack Oncology was acquired by Quest Diagnostics, Inc. on June 21, 2023 for $450 million. | Oprichter | 01-01-2021 | - |
Corporate Officer/Principal | 01-07-2021 | - |
Loopbaan van Joshua Cohen
Statistieken
Internationaal
Verenigde Staten | 2 |
Operationeel
Founder | 1 |
Corporate Officer/Principal | 1 |
Sectoraal
Health Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Haystack Oncology, Inc.
![]() Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Part of Quest Diagnostics, Inc., Haystack Oncology, Inc. is a biopharmaceutical company based in Baltimore, MD. The Haystack MRD test is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in various locations. The company developed Haystack MRD™, a next-generation tumor-informed approach for the measurement of minimal residual disease. Haystack Oncology works with biopharmaceutical companies to advance important therapeutics to markets, from early phase clinical development to companion diagnostics. The test accelerates clinical development with better MRD testing unmatched sensitivity and specificity for confident MRD detection. The company leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development. The company was founded in 2021 by Kenneth W. Kinzler, Nickolas Papadopoulos, Joshua Cohen, Bert Vogelstein, and the CEO is Dan Edelstein. Haystack Oncology was acquired by Quest Diagnostics, Inc. on June 21, 2023 for $450 million. | Health Services |
- Beurs
- Insiders
- Joshua Cohen
- Ervaring